Visit COVID-19 resources

[Skip to Content]

Field Safety Notice: Siemens Healthcare Diagnostics; samples containing fluorescein may show interference

16 May 2014

Siemens Healthcare Diagnostics advises that if blood samples contain fluorescein it may interfere with the ADVIA Centaur® Systems TSH3 Ultra, Vitamin D and the ADVIA Centaur BRAHMS Procalcitonin assay tests.

Evidence suggests that patients undergoing fluorescein angiography can retain small amounts of fluorescein dye in body fluids for up to 72 hours post angiography.

Patients should be advised not to have thyroid function or vitamin D hormone serum levels checked for 48 hours following undergone fluorescein angiography.

See the Field Safety Notice

Clinicians are reminded to report any suspected interactions to the MHRA via the Yellow Card Scheme at: